[go: up one dir, main page]

MA27590A1 - Agonistes du recepteur du facteur de liberation 2 de la corticotropine. - Google Patents

Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Info

Publication number
MA27590A1
MA27590A1 MA27778A MA27778A MA27590A1 MA 27590 A1 MA27590 A1 MA 27590A1 MA 27778 A MA27778 A MA 27778A MA 27778 A MA27778 A MA 27778A MA 27590 A1 MA27590 A1 MA 27590A1
Authority
MA
Morocco
Prior art keywords
receptor agonists
release factor
corticotropin release
corticotropin
derivatives
Prior art date
Application number
MA27778A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27590A1 publication Critical patent/MA27590A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des dérivés isolés du facteur de libération de corticotropine, et des acides nucléiques codant pour de tels dérivés, efficaces dans le traitement de troubles modulés par le récepteur du facteur 2 de libération de la corticotropine tels que la dystrophie musculaire.
MA27778A 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine. MA27590A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
MA27590A1 true MA27590A1 (fr) 2005-11-01

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Country Status (29)

Country Link
US (7) US7192924B2 (fr)
EP (4) EP1724283B1 (fr)
JP (3) JP4508649B2 (fr)
KR (3) KR100758857B1 (fr)
CN (3) CN100475844C (fr)
AR (3) AR038144A1 (fr)
AT (4) ATE398632T1 (fr)
AU (2) AU2003205197B2 (fr)
BR (3) BR0306838A (fr)
CA (3) CA2470743C (fr)
CY (1) CY1106133T1 (fr)
DE (4) DE60313845T2 (fr)
DK (2) DK1465921T3 (fr)
ES (4) ES2309909T3 (fr)
IL (5) IL162529A0 (fr)
MA (3) MA27592A1 (fr)
MX (3) MXPA04006885A (fr)
MY (1) MY140306A (fr)
NO (3) NO20043371L (fr)
NZ (3) NZ533600A (fr)
PE (3) PE20030974A1 (fr)
PL (3) PL373139A1 (fr)
PT (2) PT1465921E (fr)
RU (1) RU2294333C2 (fr)
SA (3) SA03230565B1 (fr)
SI (1) SI1465921T1 (fr)
TW (3) TW200302278A (fr)
WO (3) WO2003062268A2 (fr)
ZA (1) ZA200404995B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (fr) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
EP1871888A4 (fr) * 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic Haemophilus influenzae de type b
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2009033773A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
EP2197467A2 (fr) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Utilisation de l'adrenomedulline comme agent therapeutique pour le traitement de l'angiogense excessive
WO2009046874A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Polythérapie de peptide potentialisateur de la trh et de stresscopine
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
EP2206726A1 (fr) * 2009-01-08 2010-07-14 Universite Joseph Fourier Outils non invasifs pour la détection de plaques athérosclérotique vulnérables
EP2496248A2 (fr) * 2009-11-04 2012-09-12 Janssen Pharmaceutica, N.V. Méthode de traitement de l'insuffisance cardiaque avec des peptides de type stresscopine
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
DK2814513T3 (en) 2012-02-14 2018-02-26 Univ California Systemic administration and regulated expression of paracrine for cardiovascular disease and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途
WO2025184558A1 (fr) * 2024-02-28 2025-09-04 Caradon Therapeutics, Inc. Urocortine 3 modifiée
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
AU2025204485B2 (en) * 2024-04-30 2025-12-11 Hanmi Pharm. Co. Ltd. Use of crf2 receptor agonist and the acylated conjugates thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
EP0845035A2 (fr) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Peptides d'urocortine
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
KR100879232B1 (ko) 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
CA2427490A1 (fr) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192924B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
US20060025339A1 (en) 2006-02-02
PL373139A1 (en) 2005-08-22
US20080004435A1 (en) 2008-01-03
WO2003062268A2 (fr) 2003-07-31
CA2470656C (fr) 2011-06-28
DK1465923T3 (da) 2007-07-02
BR0306826A (pt) 2005-09-06
BR0306838A (pt) 2005-04-05
CA2470731A1 (fr) 2003-07-31
AU2003205197B2 (en) 2006-03-02
JP4489434B2 (ja) 2010-06-23
KR100758857B1 (ko) 2007-09-14
AU2003237419B2 (en) 2006-04-13
DE60313845T2 (de) 2008-01-31
EP1724283A3 (fr) 2007-04-11
PE20030849A1 (es) 2003-12-01
CN1617885A (zh) 2005-05-18
DK1465921T3 (da) 2006-11-27
CA2470743C (fr) 2011-12-13
EP1465923B1 (fr) 2007-05-16
NZ533599A (en) 2007-03-30
ZA200404995B (en) 2005-06-29
SA03230564A (ar) 2005-12-03
IL162530A0 (en) 2005-11-20
PT1465921E (pt) 2006-12-29
TW200302277A (en) 2003-08-01
US7462597B2 (en) 2008-12-09
MY140306A (en) 2009-12-31
CA2470743A1 (fr) 2003-07-31
NO20043396L (no) 2004-10-06
CN1617887A (zh) 2005-05-18
NZ533600A (en) 2007-02-23
ATE398632T1 (de) 2008-07-15
US20030148958A1 (en) 2003-08-07
US20090124793A1 (en) 2009-05-14
PE20030974A1 (es) 2003-12-26
SA03230564B1 (ar) 2006-10-31
TWI300442B (en) 2008-09-01
WO2003062277A1 (fr) 2003-07-31
MXPA04006884A (es) 2004-12-06
CN100391972C (zh) 2008-06-04
JP2005522191A (ja) 2005-07-28
SA03230565A (ar) 2005-12-03
PL373529A1 (en) 2005-09-05
IL196384A0 (en) 2011-07-31
BR0306878A (pt) 2004-10-26
CN1617886A (zh) 2005-05-18
ES2269976T3 (es) 2007-04-01
ATE362488T1 (de) 2007-06-15
SI1465921T1 (sl) 2006-10-31
NO20043366L (no) 2004-10-06
PL371364A1 (en) 2005-06-13
MXPA04006885A (es) 2004-12-06
TW200302276A (en) 2003-08-01
US7608701B2 (en) 2009-10-27
RU2004124847A (ru) 2005-04-20
MA27591A1 (fr) 2005-11-01
DE60313845D1 (de) 2007-06-28
WO2003062268A3 (fr) 2003-11-27
TW200302278A (en) 2003-08-01
CA2470656A1 (fr) 2003-07-31
US6936585B2 (en) 2005-08-30
ES2299701T3 (es) 2008-06-01
KR20040082390A (ko) 2004-09-24
ES2287484T3 (es) 2007-12-16
AR038144A1 (es) 2004-12-29
PT1465923E (pt) 2007-08-06
DE60318547T2 (de) 2008-12-24
JP4508648B2 (ja) 2010-07-21
MA27592A1 (fr) 2005-11-01
HK1078095A1 (zh) 2006-03-03
WO2003062269A2 (fr) 2003-07-31
WO2003062269A3 (fr) 2003-11-06
IL197774A0 (en) 2009-12-24
US20030148956A1 (en) 2003-08-07
EP1465921A2 (fr) 2004-10-13
SA03230565B1 (ar) 2006-10-31
DE60307044T2 (de) 2007-02-15
ES2309909T3 (es) 2008-12-16
IL162529A0 (en) 2005-11-20
US7192923B2 (en) 2007-03-20
US7192924B2 (en) 2007-03-20
ATE334147T1 (de) 2006-08-15
EP1724283B1 (fr) 2008-06-18
KR20040082389A (ko) 2004-09-24
EP1465921B1 (fr) 2006-07-26
KR100758858B1 (ko) 2007-09-14
ATE383372T1 (de) 2008-01-15
KR20040082392A (ko) 2004-09-24
US20100197579A1 (en) 2010-08-05
US7897731B2 (en) 2011-03-01
MXPA04006883A (es) 2004-12-06
DE60321730D1 (de) 2008-07-31
DE60307044D1 (de) 2006-09-07
CA2470731C (fr) 2011-06-21
AR038142A1 (es) 2004-12-29
AR038143A1 (es) 2004-12-29
US20030148957A1 (en) 2003-08-07
CY1106133T1 (el) 2011-06-08
JP2005521387A (ja) 2005-07-21
EP1465922B1 (fr) 2008-01-09
EP1465923A1 (fr) 2004-10-13
PE20030747A1 (es) 2003-10-23
IL162431A0 (en) 2005-11-20
EP1465922A2 (fr) 2004-10-13
JP2005525101A (ja) 2005-08-25
RU2294333C2 (ru) 2007-02-27
DE60318547D1 (de) 2008-02-21
NO20043371L (no) 2004-10-06
NZ533598A (en) 2007-03-30
EP1724283A2 (fr) 2006-11-22
KR100735586B1 (ko) 2007-07-04
US7632933B2 (en) 2009-12-15
JP4508649B2 (ja) 2010-07-21
CN100475844C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
MA27590A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
SG127739A1 (en) Use of immuno-regulators
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA32014B1 (fr) Composes condenses de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA27863A1 (fr) Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DE60206198D1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
EP1505990A4 (fr) Methodes de traitement de l'hepatite
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
MA29787B1 (fr) Traitement de maladies auto-immunes
MA31198B1 (fr) Nouvelle forme dosifiee
MA29723B1 (fr) Composes
MA28038A1 (fr) Thienopyrazoles
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique